Home
About
- Our Team
- Careers
News
Contact

Technology
Diagnostics
Therapeutics
- Drug Discovery
- Safer Drugs
Products
- Sales
- Licensing & Distribution
Services
Resources

AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers

July 2016/in News /by Kenneth Rothschild

Share this entry

https://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild https://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2016-07-27 13:28:402016-11-10 12:44:44AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers

Menu

Home
About
Technology
Diagnostics
Therapeutics

Products
Services
Resources
News
Contact

Get in Touch

AmberGen, Inc.

313 Pleasant St.

Watertown, MA 02472

(617) 932-9990

info@ambergen.com

Recent News

Recent Posts

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018

© 2019 - AmberGen Inc. Website designed in Massachusetts

Paper published in Nature’s Scientific Reports “Proteome-wide drug screening... AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™...

Scroll to top